Which city or region in China has a developed pharmaceutical industry (pharmacy)?

The following is the ranking of pharmaceutical industry 100 in 2009, which can be used as the basis for analyzing the situation of pharmaceutical industry in this region.

Ranked enterprise name

1 Yang Zijiang Pharmaceutical Group Co., Ltd. (including: Yang Zijiang Pharmaceutical Group Shanghai Heini Pharmaceutical Co., Ltd.)

Harbin Pharmaceutical Group Co., Ltd. (including Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.)

3 Zheng Xiu Pharmaceutical Group

4. Shi Yao Group Co., Ltd. (including Unocal Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Shijiazhuang Pharmaceutical Group Ou Yi Pharmaceutical Co., Ltd. and Shi Yao Yinhu Pharmaceutical Co., Ltd.)

Tianjin Tasly Group Co., Ltd. (including Tianjin Tasly Pharmaceutical Co., Ltd., Jiangsu Tasly First Pharmaceutical Co., Ltd. and Tianjin Tasly Modern Chinese Medicine Resources Co., Ltd.)

Gao Wei Group Co., Ltd.

7. North China Pharmaceutical Group Co., Ltd. (including North China Pharmaceutical Co., Ltd. and North China Pharmaceutical Group Preparation Co., Ltd.)

8 Northeast Pharmaceutical Group Co., Ltd.

Taiji Group Co., Ltd. (including: Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd., Taiji Group Mianyang Pharmaceutical Co., Ltd., Southwest Pharmaceutical Co., Ltd., Taiji Group Chongqing Tongjunge Pharmaceutical Factory Co., Ltd., Taiji Group Chongqing No.2 Chinese Medicine Factory, Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd., Taiji Group Zhejiang Dongfang Pharmaceutical Co., Ltd., Taiji Group Sichuan Tiancheng Pharmaceutical Co., Ltd.)

10 Beijing Shuanghe Pharmaceutical Co., Ltd. (including Anhui Shuanghe Pharmaceutical Co., Ltd., Beijing Wan Hui Shuanghe Pharmaceutical Co., Ltd., Xi An Jing Xi Shuanghe Pharmaceutical Co., Ltd., Shaanxi Jin Xin Shuanghe Pharmaceutical Co., Ltd., Beijing Shuanghe Modern Medical Technology Co., Ltd.)

1 1 China Resources Sanjiu Pharmaceutical Co., Ltd. (including Shenzhen Jiuxin Pharmaceutical Co., Ltd.)

12 Xi anjansang pharmaceutical co., ltd

13 Qilu Pharmaceutical Co., Ltd. (including Qilu Pharmaceutical (Hainan) Co., Ltd., Qilu Tianhe Huishi Pharmaceutical Co., Ltd. and Qilu Anti Pharmaceutical Co., Ltd.)

14 Zhejiang pharmaceutical co., ltd (including Xinchang pharmaceutical factory of Zhejiang pharmaceutical co., ltd and vitamin factory of Zhejiang pharmaceutical co., ltd)

15 Zhuhai lianbang pharmaceutical co., ltd

Sichuan Kelun Pharmaceutical Company Limited (including: Hunan Kelun Pharmaceutical Company Limited, Jiangxi Kelun Pharmaceutical Company Limited, Hunan Zhongnan Kelun Pharmaceutical Company Limited, Heilongjiang Kelun Pharmaceutical Company Limited, Shandong Kelun Pharmaceutical Company Limited, Hubei Tuopeng Pharmaceutical Company Limited, Kunming Nanjiang Pharmaceutical Company Limited, Liaoning Kang Min Pharmaceutical Company Limited, Sichuan Mingzhu Pharmaceutical Company Limited, Sichuan Xinyuan Pharmaceutical Company Limited, Heilongjiang Kelun Pharmaceutical Packaging Co., Ltd., Sichuan Kelun Pharmaceutical Packaging Co., Ltd., Jilin Kelun Cornell Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd.

17 Zhejiang Haizheng Pharmaceutical Co., Ltd.

18 Shanghai Fosun Pharma (Group) Co., Ltd. (including: Chongqing Yaoyou Pharmaceutical Co., Ltd., Shanghai Zhao Hui Pharmaceutical Co., Ltd., Chongqing Lin Kai Pharmaceutical Co., Ltd., Guilin Nanyao Co., Ltd. and Shanghai Clone Biotechnology Co., Ltd.)

19 Ruiyang Pharmaceutical Co., Ltd.

Furen Pharmaceutical Group Co., Ltd. (including Kaifeng (Pharmaceutical) Group Co., Ltd., Henan Furentang Pharmaceutical Co., Ltd., Henan Furen Huaiqingtang Pharmaceutical Co., Ltd. and Henan Tong Yuan Pharmaceutical Co., Ltd.)

2 1 Shandong Medical Glass Co., Ltd.

22. Pfizer Pharmaceuticals Limited

23 Zhejiang Xinhecheng Company Limited by Share Ltd

Lunan Pharmaceutical Group Co., Ltd. (including Lunan Beite Pharmaceutical Co., Ltd., Shandong New Age Pharmaceutical Co., Ltd. and Lunan Houpu Pharmaceutical Co., Ltd.)

25. Sanofi-Aventis (Hangzhou) Pharmaceutical Co., Ltd.

Renhe (Group) Development Co., Ltd.

Livzon Pharmaceutical Group Co., Ltd. (including Livzon Pharmaceutical Factory, Livzon synthesis of pharmaceuticals Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd., Livzon Fuzhou Fuxing Pharmaceutical Co., Ltd., Livzon Limin Pharmaceutical Factory, Livzon Xinbeijiang Pharmaceutical Co., Ltd. and Livzon Lida Pharmaceutical Co., Ltd.).

28 Shandong Xinhua Pharmaceutical Group Co., Ltd.

29 Hangzhou Merck Pharmaceutical Co., Ltd.

30 Beijing Novartis Pharmaceutical Co., Ltd.

3 1 Henan Tian Fang Pharmaceutical Co., Ltd.

32 China Resources Donge Ejiao Co., Ltd.

33 Zhejiang Shenghua Encyclopedia Biological Co., Ltd.

Simcere Co., Ltd. (including Hainan simcere Co., Ltd., Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd., Nanjing Dongjie Pharmaceutical Co., Ltd. and Jiangsu Shen Yan Biotechnology Co., Ltd.)

35 Shouguang Fukang Pharmaceutical Co., Ltd.

36 Henan Wanxi Pharmaceutical Co., Ltd.

37 Lijun Pharmaceutical (including Shijiazhuang No.4 Pharmaceutical Co., Ltd.)

Shandong Lu Kang Pharmaceutical Co., Ltd. (including: Shandong Lu Kang Pharmaceutical Group Saite Co., Ltd.)

39 Jiang Zhong Pharmaceutical Co., Ltd.

40 Jiangsu Jichuan Pharmaceutical Co., Ltd.

4 1 Shandong luoxin pharmaceutical co., ltd

Jiangsu Kangyuan Group Co., Ltd. (including Jiangsu Kangyuan Pharmaceutical Co., Ltd., Jiangsu Nanxing Pharmaceutical Co., Ltd., Lianyungang Kangbeier Medical Equipment Co., Ltd. and Lianyungang Hexingtang Chinese Herbal Pieces Processing Factory)

43 Qinhuangdao Lihua Starch Co., Ltd.

Guangzhou Baiyun Mountain Pharmaceutical Co., Ltd. (including: Guangzhou Baiyun Mountain Hutchison Whampoa Chinese Medicine Co., Ltd., Guangzhou Baiyun Mountain Tianxin Pharmaceutical Co., Ltd., Guangzhou Baiyun Mountain Star Pharmaceutical Co., Ltd., Guangzhou Baiyun Mountain Guanghua Pharmaceutical Co., Ltd. and Guangzhou Baxter Qiaoguang Medical Products Co., Ltd.)

45 Shandong Zibo Shanchuan Medical Equipment Co., Ltd.

46 Jiangsu Zheng Da Tianqing Pharmaceutical Co., Ltd.

47 Shijiazhuang Yiling Pharmaceutical Co., Ltd.

48 Luomei Pharmaceutical Co., Ltd.

49 Chengdu Di 'ao Group

50 Anhui Fengyuan Pharmaceutical Co., Ltd.

5 1 Zhejiang Jianfeng Pharmaceutical Co., Ltd.

52. Shandong Lvye Pharmaceutical Co., Ltd.

53 Guangzhou Wanglaoji Pharmaceutical Co., Ltd.

54 Wuhan Renfu Pharmaceutical Group Co., Ltd.

55 Zhejiang Kang Pharmaceutical Co., Ltd

56 Shandong Xianhe Pharmaceutical Co., Ltd.

57 Lu Kang Chen Xin Pharmaceutical Co., Ltd.

Omron (Dalian) co., ltd

59 Zhejiang Xianju Pharmaceutical Co., Ltd.

60 Jiangsu Aosaikang Pharmaceutical Co., Ltd.

6 1 Donggang Industry and Trade Group Co., Ltd.

62 Tiansheng Pharmaceutical Group Co., Ltd.

63 Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

Jiangsu suzhong pharmaceutical group co., ltd.

65 Hualan Biological Engineering Co., Ltd. (including Hualan Biological Vaccine Co., Ltd.)

66 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

67 Beijing Tongrentang Technology Development Co., Ltd.

68 Shanxi Weiqida Pharmaceutical Co., Ltd.

Shanghai Hyundai Pharmaceutical Co., Ltd. (including Shanghai Hyundai Hasen (Shangqiu) Pharmaceutical Co., Ltd.)

70 Yuekang Pharmaceutical Group Co., Ltd

7 1 guilin sanjin group co., ltd (including: guilin sanjin pharmaceutical co., ltd, Sanjin guilin sanjin biopharmaceutical co., ltd and Sanjin Hunan Sanjin pharmaceutical co., ltd).

72 Ningxia Qiyuan Pharmaceutical Co., Ltd.

73 Jiuzhitang Company Limited

74. Shanghai Xinya Pharmaceutical Co., Ltd

75 Jiangsu Hua En Pharmaceutical Co., Ltd.

76 Heilongjiang Sunflower Pharmaceutical Co., Ltd.

77 Anqiu Lu 'an Pharmaceutical Co., Ltd.

78 Heze Ruiying Pharmaceutical Group Co., Ltd.

79 Beijing Fei Sen Juskabi Pharmaceutical Co., Ltd.

Guizhou Baiyi Pharmaceutical Co., Ltd. (including Guilin Baiyi Lijiang Pharmaceutical Co., Ltd. and Hainan Changan International Pharmaceutical Co., Ltd.)

8 1 Shenzhen Zhijun Pharmaceutical Co., Ltd.

82 Disha Pharmaceutical Group Co., Ltd

83 Jiangsu Lianhuan Pharmaceutical Group Co., Ltd.

Jiangsu yabang Pharmaceutical Group Co., Ltd. (including Jiangsu yabang Epson Pharmaceutical Co., Ltd., Jiangsu yabang Shengyuan Pharmaceutical Co., Ltd. and Jiangsu yabang Johnson Pharmaceutical Co., Ltd.)

85 Hengdian Group Kangyu Drug Co., Ltd.

86 Zheng Da Qingchunbao Pharmaceutical Co., Ltd.

87 Lanzhou Institute of Biological Products

88 Shandong Tian Li Pharmaceutical Co., Ltd.

89 Fujian Fukang Drug Co., Ltd.

90 Sichuan Zhongshu Pharmaceutical Co., Ltd.

9 1 Beijing Tongrentang Healthy Pharmaceutical Co., Ltd.

92. Anstalay Pharmaceutical (China) Co., Ltd.

93 Shanghai Xin Xianfeng Pharmaceutical Co., Ltd.

94 Xianyang Buchang Pharmaceutical Co., Ltd.

95 Zhejiang Huahai Pharmaceutical Co., Ltd.

96 Liaoning Nuokang Biopharmaceutical Co., Ltd.

97 Beijing Taide Pharmaceutical Co., Ltd.

98 Zhejiang Hailisheng Pharmaceutical Co., Ltd.

99 Shandong xinhua medical Machinery Group

100 Shanghai Baxter Medical Products Co., Ltd.

The following are the development trends of the industry:

In the past year, the domestic pharmaceutical industry frequently experienced the integration of giants, and the pharmaceutical sectors of Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Shanghai Pharmaceutical Group") and Shanghai Industrial (Group) Co., Ltd. (hereinafter referred to as "SIIC Group") took the lead in merging to form a new Shanghai Pharmaceutical Company. China Pharmaceutical Group Corporation (hereinafter referred to as "Sinopharm Group") successfully reorganized Shanghai Pharmaceutical Industry Research Institute (hereinafter referred to as "Medical Engineering Institute") and established a new Sinopharm after merging with China Biotechnology Group Corporation (hereinafter referred to as "Zhongsheng Group") last year. Just before this, on 10, China Resources Group and the Beijing Municipal People's Government formally signed the Framework Agreement on Strategic Cooperation between * * * and the Development of Pharmaceutical Industry and Microelectronics Industry, and China Resources officially took North Pharmaceutical into its arms and established the new China Resources. At this point, with the completion of the merger and reorganization of the three major domestic pharmaceutical giants, the M&A transaction amount of the pharmaceutical industry has reached the highest level since 2000, and the competitive pattern of the pharmaceutical market has obviously changed, and the pharmaceutical industry in China has officially entered the Three Kingdoms era. The three seats of New Sinopharm, New China Resources and New Shanghai Medicine have been scheduled, and the industry leaders have surfaced after rearrangement. Recently, the idea of establishing several medical leading groups in China as required by the state has been initially realized.

New ethnic medicine

The undisputed leader of the pharmaceutical industry in China is still the New Sinopharm Group. 12 In April, the Institute of Medical Engineering was merged into Sinopharm Group as a whole and became its wholly-owned subsidiary. The number of enterprises that SASAC performed the responsibilities of investors was adjusted from 65,438+027 to 65,438+026. The integration of medical engineering colleges is of great significance to China medical science. Although Sinopharm Group is the absolute leader in the domestic pharmaceutical industry, 80% of its profits come from pharmaceutical enterprises represented by Sinopharm Holdings. Even though the restructured biological products of Zhongsheng Group have sustained high profit contribution, it is always difficult to hide the obvious shortcomings of Sinopharm in the pharmaceutical industry. The more urgent problem is that the first integrated new drug is firmly in East China, and another central enterprise giant, China Resources Group, has never stopped its ambition and pace of acquisition. Driven by the sinking of the grassroots of the new medical reform, regional leaders are not to be outdone, and they have formed alliances to confront each other. Under the "internal troubles and foreign invasion", the Institute of Medical Engineering has become a trump card that Chinese medicine must win.

In the field of medical research in China, the Academy of Medical Engineering has always been a proud existence-as the only research institution in the medical industry in the sequence of central enterprises, the Academy of Medical Engineering has successively been subordinate to the Central Enterprise Working Committee and the State-owned Assets Supervision and Administration Commission of the State Council. In the pharmaceutical sector of Shanghai and Shenzhen stock markets, more than 30 listed companies take scientific research achievements as their main products, with the target revenue of 20 10/0/500 million yuan. Their main business is the research and development of innovative drugs, drug production and sales, and their research and development strength is second to none in the country. Although the annual operating income is less than 1 100 million yuan, its powerful scientific research force has become the industrial engine and fission device of Sinopharm Group. Two industrial enterprises under the Academy of Medical Engineering, Hyundai Pharmaceutical and Shanghai Modern Pharmaceutical Preparation Engineering Research Center Co., Ltd., have achieved good results, and their economic and social benefits are even difficult to evaluate.

On April 22nd, China Pharmaceutical Group and Shanxi Wichita Pharmaceutical Co., Ltd. (hereinafter referred to as "Wichita") signed an agreement in Datong, Shanxi, and Sinopharm Group officially started the restructuring of Wichita. Sinopharm Group promised to hold Wichita through equity acquisition and capital increase and share expansion. This is the first step of independent merger and acquisition of Sinopharm Group in the pharmaceutical industry, which is of great significance and can accelerate the industrialization process of Sinopharm. At the same time, after Sinopharm acquired Wichita, it will definitely open a breakthrough in Shanxi and introduce other businesses into this area. Wichita is the main manufacturer of pharmaceutical intermediate 7-ACA in China, and the direct downstream product of this intermediate is ceftriaxone sodium. China is a big country that uses anti-infective drugs, and the anti-infective drugs in China are growing rapidly at an average annual rate of about 17%. In 2009, the market scale of anti-infective drugs in China has exceeded 40 billion yuan. Ceftriaxone sodium has always been the first-selling drug of antibiotics. In 2008, China Pharmaceutical Association made statistics on 22 hospitals in China, and the amount of ceftriaxone sodium used reached 269.78 million yuan, far exceeding other drugs. Unocon and Fuzhou Antibiotics Group are the main producers of 7-ACA, with an annual production capacity of about10.6 million tons. Wichita ranks third, about 1000 tons, and the annual production capacity of enterprises such as Health Yuan is below 800 tons. In the restructuring agreement, Sinopharm Holdings said that it would further expand Wichita's production capacity and realize the production scale of 65,438+0,200 tons of 7-ACA and 300 tons of clavulanic acid. And it is planned that by 20 15, Wichita's sales revenue will exceed 3 billion yuan.

Sinopharm Group, as a platform for SASAC to integrate pharmaceutical central enterprises, had acquired Zhongsheng Group on September 16, 2009 before winning the Academy of Medical Engineering and Wichita. With its exclusive monopoly on vaccine business and blood products business, Zhongsheng Group has become a huge king kong of Sinopharm Group, which is of absolute significance to Sinopharm Group. Zhongsheng Group made up for the shortage of blood and vaccine business of Sinopharm Group. This move is in line with SASAC's long-term strategy of building Sinopharm Group into a large-scale pharmaceutical group integrating trade, science and engineering. Zhongsheng Group has become the eighth largest business segment of Sinopharm Group. Previously, Zhongsheng Group was the largest supplier of vaccines and blood products in China, mainly engaged in the manufacture and sales of vaccines, blood products and diagnostic reagents. 90% of the planned vaccines in China come from Zhongsheng Group, with a revenue of 4.9 billion yuan in 2008.

At present, according to Song Zhiping, chairman of Sinopharm Group, the sales ranking of Sinopharm Group should be squeezed into the top 40 before the end of 20 10 and enter the top 30 of the "30~50 internationally competitive enterprises" proposed by the central government. In 2009, Sinopharm Group achieved an operating income of 65 billion yuan and a profit of 3.63 billion yuan, ranking first in the pharmaceutical industry in China. Among 129 central enterprises, the two indicators ranked 50th and 38th respectively. This year and next, the sales revenue targets of Sinopharm Holdings are set at 80 billion yuan and 654.38+000 billion yuan respectively. The long-term goal of Sinopharm Group is to enter the world's top 500 in 20 15 years. According to the forecast of Sinopharm Group, the entry threshold of the world's top 500 companies is about 654.38+060 billion yuan in terms of sales revenue.

Xin huarun

China Resources Pharmaceutical Group is another masterstroke of SASAC's "Building a Medical Platform for Central Enterprises". On the basis of reorganizing the medical resources of central enterprises Huayuan Group and Sanjiu Group, China Resources has grown into a large-scale pharmaceutical manufacturing and circulation enterprise. With an annual turnover of over 27 billion yuan, China Resources Pharmaceutical owns well-known pharmaceutical enterprises such as Beijing Pharmaceutical, Sanjiu Pharmaceutical and China Resources Dong 'e Ejiao, and directly or indirectly holds several listed companies such as Sanjiu Pharmaceutical, Dong 'e Ejiao, Shuanghe Pharmaceutical and Wandong Medical. Pharmaceutical industry, consumer goods, electricity and real estate are listed as the first-class profit centers of China Resources Group. China Resources has occupied three main markets in Shanghai, Beijing and Shenzhen in the pharmaceutical sector, and its regional layout is relatively formed. Under the favorable list of essential drugs released by medical reform last year, Sanjiu Medicine, which has brand advantages in OTC and Chinese pharmacy, has undoubtedly injected new vitality into China Resources. On the afternoon of April 2, 2065438+00, China Resources and Beijing Pharmaceutical Co., Ltd. formally signed the Framework Agreement on Strategic Cooperation between China Resources and Beijing Municipal People's Government on the Development of Pharmaceutical Industry and Microelectronics Industry. China resources' shareholding in Beijing pharmaceutical co., ltd may be locked at 5%~ 10%. The signing of the strategic agreement has enabled China Resources Group to successfully complete the transformation of ranking three into two.

It is of great significance for China Resources to reorganize North Medicine. From June 5438 to February 2006, China Resources acquired 50% shares of Beijing Pharmaceutical held by Huayuan in cash and became the largest shareholder of Beijing Pharmaceutical Group. In fact, China Resources has never been involved in the operation and management of Beijing Pharmaceutical Group, and its desire to further increase its holdings has not been clearly stated by the Beijing Municipal Government for several years. At the same time, with the announcement of the completion of the reorganization of Sinopharm Group, Zhongsheng Group and Academy of Medical Sciences, China Resources is facing increasing pressure. If you can't catch the northern medicine again, you will be thrown away by your opponent. At the same time, the State-owned Assets Supervision and Administration Commission (SASAC) redefined Sinopharm as a medical platform for central enterprises, and China Resources was under great pressure. It is hoped that through this integration, the pharmaceutical assets of China Resources Pharmaceutical Group will be merged with Beijing Pharmaceutical Group. China Resources is likely to build a platform for China Resources New Pharmaceutical Group based on Beijing Pharmaceutical Group and regain its position in the pharmaceutical industry of central enterprises. After the reorganization of Beijing Pharmaceutical Co., Ltd., the medical assets controlled by China Resources will include Beijing Pharmaceutical Co., Ltd., China Resources Sanjiu Co., Ltd. and Dong 'e Ejiao Co., Ltd., covering Chinese medicine, health care products, pharmaceutical circulation, medical devices and other fields. China Resources can not only build a brand-new platform for China Resources Pharmaceutical Group by relying on Beijing Pharmaceutical Group, but also form a pharmaceutical pattern of "Northern Medicine on the top and Sanjiu on the bottom", and its overall scale also surpasses new drugs, ranking second in the country. In 2009, the sales revenue of Beijing Pharmaceutical Co., Ltd. was 26.9 billion yuan, ranking third among the national pharmaceutical enterprises. With the acquisition of Beijing Pharmaceuticals, the revenue of China Resources Pharmaceuticals in 2009 can be increased to 33.7 billion yuan, surpassing the newly added medicines, ranking second in China.

New applied medicine

Although the new Shanghai pharmaceutical group has fallen to the third place in the industry, the action of seeking integration and growth has started very early. From June 5438 to 10, 2009, Shanghai Pharmaceutical, a subsidiary of Shanghai Pharmaceutical Group, integrated the pharmaceutical assets of SIIC Group and Shanghai Pharmaceutical Group by absorbing, merging and issuing shares to purchase assets. A new Shanghai medicine came into being and became a platform for the integration of pharmaceutical industry resources under the state-owned assets of Shanghai. At the beginning of 20 10, Xinshangyao acquired four foreign-funded pharmaceutical companies in one breath, and signed an acquisition framework agreement with Guangzhou Zhongshan Pharmaceutical Co., Ltd., Shandong Shanglian Biochemical Pharmaceutical Co., Ltd. and Changzhou yabang Pharmaceutical Co., Ltd.

In 2009, the total assets of new drugs jumped from 8 billion yuan to 22.3 billion yuan, the sales revenue jumped from 23 billion yuan to 30 billion yuan, and the net profit was 880 million yuan, making it the second largest pharmaceutical group in China after Sinopharm Group at that time, and now it has been left behind by China Resources. Although it does not belong to the sequence of central enterprises, the pharmaceutical commercial sales scale of the reorganized Xinshangyao Group has ranked first in East China. The plan of medical application is that the income from 20 12 will reach 50 billion yuan, and the income from 20 13 will reach 80 billion yuan if more than 35 varieties exceed 100 million yuan.